Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/30/2020 03/31/2020 04/01/2020 04/02/2020 04/03/2020 Date
75.93(c) 74.76(c) 72.51(c) 76.98(c) 78.21(c) Last
15 929 392 12 120 987 12 177 608 20 482 067 19 103 292 Volume
+4.23% -1.54% -3.01% +6.16% +1.60% Change
More quotes
Financials (USD)
Sales 2020 22 418 M
EBIT 2020 10 567 M
Net income 2020 6 903 M
Finance 2020 6 946 M
Yield 2020 3,53%
Sales 2021 22 159 M
EBIT 2021 10 228 M
Net income 2021 6 671 M
Finance 2021 9 433 M
Yield 2021 3,71%
P/E ratio 2020 14,2x
P/E ratio 2021 14,4x
EV / Sales2020 4,01x
EV / Sales2021 3,95x
Capitalization 96 919 M
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
07:15aRecession Blue-Chips' Led the Way in Another Turbulent Week in Markets
DJ
06:51aGILEAD SCIENCES : Company - Kite Licenses Antibodies and Establishes Collaborati..
AQ
04/02GILEAD SCIENCES : Kite Licenses Antibodies and Establishes Collaboration With Te..
BU
03/31GILEAD SCIENCES : Report
CO
03/30GILEAD : Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seve..
BU
03/28GILEAD SCIENCES : Revamps Process for Emergency Requests for Experimental Corona..
DJ
03/28GILEAD SCIENCES : Limits Access to Experimental Coronavirus Drug Due to High Dem..
DJ
03/25GILEAD SCIENCES : Withdraws Application for Orphan-Drug Status
DJ
03/25GILEAD SCIENCES : Statement on Request to Rescind Remdesivir Orphan Drug Designa..
PU
03/24GILEAD SCIENCES : Potential coronavirus treatment granted rare disease status
AQ
03/23GILEAD SCIENCES : Amendment to a previously filed SC TO-T
PU
03/23GILEAD SCIENCES : Statement on Ensuring Continued Supply of HIV Medicine Amid Co..
PU
03/23H&R Block, Macy's fall; Avis Budget, PG&E rise
AQ
03/22GILEAD SCIENCES : Statement on Access to Remdesivir Outside of Clinical Trials
PU
03/22GILEAD SCIENCES : puts emergency access to experimental coronavirus drug on hold..
RE
More news
News in other languages on GILEAD SCIENCES
03/30Wall Street, saluant des mesures sanitaires, poursuit son rebond
03/30VIRUS/ÄRZTE OHNE GRENZEN : Keine Patente bei Corona-Medikamenten
03/17DZ Bank hebt Gilead Sciences auf 'Kaufen' - Ziel 80 Dollar
03/17GILEAD SCIENCES : Der große Profiteur der Coronavirus-Krise?
03/12GILEAD SCIENCES : Ex-dividend day for
More news
Stock Trading Strategies
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 75,48  $
Last Close Price 76,98  $
Spread / Highest target 16,9%
Spread / Average Target -1,95%
Spread / Lowest Target -24,7%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES20.36%94 124
VERTEX PHARMACEUTICALS10.60%61 693
REGENERON PHARMACEUTICALS32.83%53 154
WUXI APPTEC CO., LTD.1.90%21 017
GENMAB A/S-6.92%13 229
BEIGENE, LTD.-17.74%9 553